DANAHER CORPORATION
|
||
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
Delaware
|
|
001-08089
|
|
59-1995548
|
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
||
2200 Pennsylvania Avenue, NW
|
|
|
|
20037-1701
|
|
Suite 800W
|
|
|
|
||
Washington,
|
DC
|
|
|
|
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.01 par value
|
DHR
|
New York Stock Exchange
|
4.75% Mandatory Convertible Preferred Stock, Series A, without par value
|
DHR PR A
|
New York Stock Exchange
|
Floating Rate Senior Notes due 2022
|
DHR F 06/30/22
|
New York Stock Exchange
|
1.700% Senior Notes due 2022
|
DHR 1.7 01/04/22
|
New York Stock Exchange
|
1.700% Senior Notes due 2024
|
DHR 1.7 03/30/24
|
New York Stock Exchange
|
2.500% Senior Notes due 2025
|
DHR 2.5 07/08/25
|
New York Stock Exchange
|
0.200% Senior Notes due 2026
|
DHR 0.2 03/18/26
|
New York Stock Exchange
|
2.100% Senior Notes due 2026
|
DHR 2.1 09/30/26
|
New York Stock Exchange
|
1.200% Senior Notes due 2027
|
DHR 1.2 06/30/27
|
New York Stock Exchange
|
0.450% Senior Notes due 2028
|
DHR 0.45 03/18/28
|
New York Stock Exchange
|
2.500% Senior Notes due 2030
|
DHR 2.5 03/30/30
|
New York Stock Exchange
|
0.750% Senior Notes due 2031
|
DHR 0.75 09/18/31
|
New York Stock Exchange
|
1.350% Senior Notes due 2039
|
DHR 1.35 09/18/39
|
New York Stock Exchange
|
1.800% Senior Notes due 2049
|
DHR 1.8 09/18/49
|
New York Stock Exchange
|
Emerging growth company
|
|
☐
|
Exhibit Number
|
|
Exhibit Description
|
|
|
|
1.1
|
|
|
|
|
|
1.2
|
|
|
|
|
|
3.1
|
|
|
|
|
|
4.1
|
|
|
|
|
|
5.1
|
|
|
|
|
|
5.2
|
|
|
|
|
|
23.1
|
|
|
|
|
|
23.2
|
|
|
|
|
|
101.INS
|
|
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
|
|
|
|
101.SCH
|
|
Inline XBRL Taxonomy Extension Schema Document
|
|
|
|
101.CAL
|
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.DEF
|
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
101.LAB
|
|
Inline XBRL Taxonomy Extension Labels Linkbase Document
|
|
|
|
101.PRE
|
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
104
|
|
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
|
|
DANAHER CORPORATION
|
|
|
|
|
Date: May 12, 2020
|
By:
|
/s/ James F. O'Reilly
|
|
|
Name: James F. O'Reilly
|
|
|
Title: Vice President, Associate General Counsel and Secretary
|
SECTION 1.
|
Representations and Warranties.
|
SECTION 2.
|
Sale and Delivery to Underwriters; Closing.
|
SECTION 3.
|
Covenants of the Company. The Company covenants with each Underwriter as follows:
|
SECTION 4.
|
Payment of Expenses.
|
SECTION 5.
|
SECTION 5. Conditions of Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations and warranties of the Company contained in Section 1 hereof or in certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions:
|
SECTION 6.
|
Indemnification.
|
SECTION 7.
|
Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.
|
SECTION 8.
|
Representations, Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company, and (ii) delivery of and payment for the Securities.
|
SECTION 9.
|
Termination of Agreement.
|
SECTION 10.
|
Default by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such 24-hour period, then:
|
SECTION 11.
|
Tax Disclosure. Notwithstanding any other provision of this Agreement, from the commencement of discussions with respect to the transactions contemplated hereby, the Company (and each employee, representative or other agent of the Company) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure (as such terms are used in Sections 6011, 6111 and 6112 of the U.S. Code and the Treasury Regulations promulgated thereunder) of the transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to the Company relating to such tax treatment and tax structure.
|
SECTION 12.
|
Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Control Room; J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358), Attention: Equity Syndicate Desk, Citigroup Global Markets Inc., 388 Greenwich Street, New York, NY 10013, Facsimile: (646) 291-1469, Attention: General Counsel; and Evercore Group L.L.C., 55 East 52nd Street, New York, NY 10055, Attention: Kenneth A. Masotti, Esq., Fax: 212-857-3101, with a copy to Latham & Watkins LLP, 885 3rd Avenue, New York, NY 10022, Attention: Greg Rodgers.
|
SECTION 13.
|
Recognition of the U.S. Special Resolution Regimes.
|
SECTION 14.
|
No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the
|
SECTION 15.
|
Integration. This Agreement supersedes all prior agreements and understandings (whether written or oral) among the Company and the Underwriters, or any of them, with respect to the subject matter hereof.
|
SECTION 16.
|
Parties. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.
|
SECTION 17.
|
GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
|
SECTION 18.
|
TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
|
SECTION 19.
|
Waiver of Right to Trial by Jury. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
|
SECTION 20.
|
Submission to Jurisdiction. The Company irrevocably submits to the non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York over any suit, action or proceeding arising out of or relating to this Agreement. The Company irrevocably waives, to the full extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in such a court and any claim that any such suit, action or proceeding brought in such a court has been brought in an inconvenient forum. To the extent that the Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to itself or its property, the Company irrevocably waives, to the full extent permitted by law, such immunity in respect of any such suit, action or proceeding. The Company waives, to the full extent permitted by law, any other requirements of or objections to personal jurisdiction with respect thereto.
|
SECTION 21.
|
Counterparts; Electronic Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same Agreement. Delivery of an executed Agreement by one party to the other may be made by facsimile, electronic mail or other transmission method as permitted by applicable law, and the parties hereto agree that any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. A party’s electronic signature (complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. §§ 301-309), as amended from time to time, or other applicable law) of this Agreement shall have the same validity and effect as a signature affixed by the party’s hand.
|
SECTION 22.
|
Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.
|
Very truly yours,
|
|
|
|
DANAHER CORPORATION
|
|
|
|
By:
|
/s/ Matthew McGrew
|
|
Name: Matthew McGrew
|
|
Title: Executive Vice President
and Chief Financial Officer
|
CONFIRMED AND ACCEPTED,
as of the date first above written:
|
|
|
|
GOLDMAN SACHS & CO. LLC
|
|
|
|
By:
|
/s/ Elizabeth Wood
|
|
Name: Elizabeth Wood
Title: MD
|
|
|
J.P. Morgan Securities LLC
|
|
|
|
By:
|
/s/ David Ke
|
|
Name: David Ke
Title: Executive Director
|
|
|
|
|
CITIGROUP GLOBAL MARKETS INC.
|
|
|
|
By:
|
/s/ Richard Duffield
|
|
Name: Richard Duffield
Title: Managing Director |
|
|
|
|
EVERCORE GROUP L.L.C.
|
|
|
|
By:
|
/s/ James R. Birle, Jr.
|
|
Name: James R. Birle, Jr.
Title: Senior Managing Director |
Name of Underwriter
|
|
Number of Initial Securities to
be Purchased
|
Goldman Sachs & Co. LLC
|
|
2,852,762
|
J.P. Morgan Securities LLC
|
|
1,901,841
|
Citigroup Global Markets Inc.
|
|
1,426,380
|
Evercore Group L.L.C.
|
|
1,426,380
|
Credit Suisse Securities (USA) LLC
|
|
713,190
|
BTIG, LLC
|
|
118,865
|
Commerz Markets LLC
|
|
118,865
|
Mizuho Securities USA LLC
|
|
118,865
|
MUFG Securities Americas Inc.
|
|
118,865
|
Raymond James & Associates, Inc.
|
|
118,865
|
RBC Capital Markets, LLC
|
|
118,865
|
Scotia Capital (USA) Inc.
|
|
118,865
|
SMBC Nikko Securities, Inc.
|
|
118,865
|
TD Securities (USA) LLC
|
|
118,865
|
Wells Fargo Securities, LLC
|
|
118,865
|
|
|
|
Total
|
|
9,509,203
|
1.
|
Pricing Term Sheet, dated May 7, 2020, relating to the Securities, as filed pursuant to Rule 433 under the Securities Act and attached to this Agreement as Schedule D.
|
1.
|
Investor Presentation, dated May 2020.
|
Issuer:
|
Danaher Corporation
|
Trade Date:
|
May 8, 2020
|
Expected Settlement Date:
|
May 12, 2020 (T+2)
|
by Danaher Corporation:
|
9,509,203 shares of common stock, par value $0.01 per share (“Common Stock”), of Danaher Corporation
|
Danaher Corporation:
|
Up to 1,426,379 shares of Common Stock that the underwriters for the Common Stock Offering have the option to purchase from Danaher Corporation.
|
Symbol / Exchange:
|
DHR / NYSE
|
on the NYSE on May 7, 2020:
|
$163.48 per share
|
Public Offering Price:
|
$163.00 per share
|
Net Proceeds:
|
The net proceeds of the Common Stock Offering will be approximately $1.50 billion (or approximately $1.73 billion if the underwriters exercise their option to purchase additional shares of Common Stock in full), after deducting estimated expenses and underwriting discounts and commissions. Danaher Corporation intends to use the net proceeds from the Common Stock Offering and the Series B Mandatory Convertible Preferred Stock Offering for general corporate purposes, which may include, without limitation and in its sole discretion, funding potential future acquisitions and investments, working capital, capital expenditures, investments in or loans to its subsidiaries, refinancing of outstanding indebtedness, refinancing of outstanding capital securities, share repurchases (including, but not limited to, repurchases of its common stock), dividends and satisfaction of other obligations. The precise amounts and timing of these use of proceeds will depend on Danaher Corporation’s funding requirements and those of its subsidiaries.
|
CUSIP / ISIN:
|
235851102 / US2358511028
|
Joint Book-Running Managers:
|
Goldman Sachs & Co. LLC
|
Co-Managers:
|
BTIG, LLC
|
Title of Securities:
|
5.00% Mandatory Convertible Preferred Stock, Series B, without par value, of Danaher Corporation (the “Series B Mandatory Convertible Preferred Stock”)
|
Offered by Danaher Corporation:
|
1,550,000 shares
|
Danaher Corporation:
|
Up to an additional 167,500 shares that the underwriters for the Series B Mandatory Convertible Preferred Stock Offering have the option to purchase, solely to cover over-allotments, if any.
|
Public Offering Price:
|
$1,000.00 per share
|
Insider Participation:
|
One or more entities or individuals affiliated with Steven Rales, the Chairman of our Board, or Mitchell Rales, one of our directors and Chairman of our Executive Committee (collectively, the “Affiliated Entities”), have agreed to purchase 93,300 shares of Series B Mandatory Convertible Preferred Stock (representing an aggregate liquidation preference of up to $93.3 million) in this offering at the public offering price for investment purposes. The underwriters will not receive any underwriting discounts or commissions on any shares of Series B Mandatory Convertible Preferred Stock sold to the Affiliated Entities.
|
Net Proceeds:
|
The net proceeds of the Series B Mandatory Convertible Preferred Stock Offering will be approximately $1.51 billion (or approximately $1.67 billion if the underwriters exercise their over-allotment option in full), after deducting estimated expenses and underwriting discounts and commissions. Danaher Corporation intends to use the net proceeds from the Series B Mandatory Convertible Preferred Stock Offering and the Common Stock Offering for general corporate purposes, which may include, without limitation and in its sole discretion, funding potential future acquisitions and investments, working capital, capital expenditures, investments in or loans to its subsidiaries, refinancing of outstanding indebtedness, refinancing of outstanding capital securities, share repurchases (including, but not limited to, repurchases of its common stock), dividends and satisfaction of other obligations. The precise amounts and timing of these use of proceeds will depend on Danaher Corporation’s funding requirements and those of its subsidiaries.
|
Liquidation Preference:
|
$1,000.00 per share
|
Dividends:
|
5.00% of the liquidation preference of $1,000 per share of the Series B Mandatory Convertible Preferred Stock per annum. Dividends shall accumulate from the most recent date as to which dividends shall have been paid or, if no dividends have been paid, from the first original issue date, whether or not in any dividend period or periods there have been funds legally available for the payment of such dividends, and, to the extent that
|
Floor Price:
|
$57.05, subject to adjustment as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Dividend Payment Dates:
|
January 15, April 15, July 15 and October 15 of each year, commencing on July 15, 2020, to, and including, April 15, 2023.
|
Dividend Record Dates:
|
The December 31, March 31, June 30 or September 30, as applicable, immediately preceding the applicable Dividend Payment Date.
|
Dividend Threshold:
|
$0.18 per share, subject to adjustment as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Initial Price:
|
$163.00, which equals the per share public offering price of the Common Stock in the Common Stock Offering.
|
Threshold Appreciation Price:
|
$199.68, which represents an appreciation of 22.5% over the Initial Price.
|
Mandatory Conversion Date:
|
The second business day immediately following the last Trading Day of the 20 consecutive Trading Day period beginning on, and including, the 21st scheduled Trading Day immediately preceding April 15, 2023. The Mandatory Conversion Date is expected to be April 15, 2023.
|
Conversion Rate:
|
Upon conversion on the mandatory conversion date, the conversion rate for each share of the Series B Mandatory Convertible Preferred Stock will be not more than 6.1349 shares of Common Stock (the “Maximum Conversion Rate”) and not less than 5.0081 shares of Common Stock (the “Minimum Conversion Rate”), with the exact conversion rate depending on the Applicable Market Value of the Common Stock, as described in, and subject to certain anti-dilution adjustments that are described in, the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement. The following table illustrates hypothetical conversion rates per share of the Series B Mandatory Convertible Preferred Stock, subject to certain anti-dilution adjustments that are described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Applicable Market Value
of the Common Stock
|
|
Conversion rate (number of shares
of Common Stock to be received
upon conversion of each share of the
Series B Mandatory Convertible Preferred Stock)
|
|
|
|
Greater than $199.68 (which is
the Threshold Appreciation Price)
|
|
5.0081 shares (approximately equal to $1,000 divided
by the Threshold Appreciation Price) (the initial
Minimum Conversion Rate)
|
|
|
|
Equal to or less than $199.68 but
greater than or equal to $163.00
|
|
Between 5.0081 and 6.1349 shares, determined by
dividing $1,000 by the Applicable Market Value
of the Common Stock
|
|
|
|
Less than $163.00 (which is the
Initial Price)
|
|
6.1349 shares (approximately equal to
$1,000 divided by the Initial Price) (the initial
Maximum Conversion Rate)
|
of the Holder:
|
At any time prior to April 15, 2023, other than during a Fundamental Change Conversion Period (as defined below), holders of the Series B Mandatory Convertible Preferred Stock have the option to elect to convert their shares of the Series B Mandatory Convertible Preferred Stock in whole or in part (but in no event less than one share of the Series B Mandatory Convertible Preferred Stock), into shares of Common Stock at the Minimum Conversion Rate of 5.0081 shares of Common Stock per share of Series B Mandatory Convertible Preferred Stock as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement. This Minimum Conversion Rate is subject to certain anti-dilution adjustments as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Dividend Make-Whole Amount:
|
If a Fundamental Change occurs on or prior to April 15, 2023, holders of the Series B Mandatory Convertible Preferred Stock will have the option to convert their shares of Series B Mandatory Convertible Preferred Stock, in whole or in part (but in no event less than one share of the Series B Mandatory Convertible Preferred Stock), into Common Stock at the Fundamental Change Conversion Rate during the period (“Fundamental Change Conversion Period”) beginning on the effective date of such Fundamental Change and ending on, and including, the date that is 20 calendar days after the Effective Date of such Fundamental Change (or, if earlier, April 15, 2023). The Fundamental Change Conversion Rate will be determined based on the Effective Date of the Fundamental Change and the price paid or deemed paid per share of the Common Stock in such Fundamental Change.
|
Conversion Rate:
|
The “Fundamental Change Conversion Rate” will be determined by reference to the table below and is based on the Effective Date and the Stock Price. If the holders of Common Stock receive only cash in the Fundamental Change, the Stock Price shall be the cash amount paid per share of Common Stock. Otherwise, the Stock Price shall be the Average VWAP per share of Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day preceding the Effective Date.
|
|
|
Stock Price
|
||||||||||||||||||||||
Effective Date
|
|
$100.00
|
|
$120.00
|
|
$140.00
|
|
$163.00
|
|
$180.00
|
|
$199.68
|
|
$220.00
|
|
$240.00
|
|
$260.00
|
|
$280.00
|
|
$300.00
|
|
$320.00
|
May 12, 2020
|
|
5.7253
|
|
5.6137
|
|
5.4906
|
|
5.3571
|
|
5.2713
|
|
5.1880
|
|
5.1196
|
|
5.0673
|
|
5.0275
|
|
4.9976
|
|
4.9753
|
|
4.9588
|
April 15, 2021
|
|
5.8696
|
|
5.7579
|
|
5.6171
|
|
5.4527
|
|
5.3438
|
|
5.2383
|
|
5.1531
|
|
5.0905
|
|
5.0449
|
|
5.0126
|
|
4.9900
|
|
4.9745
|
April 15, 2022
|
|
6.0298
|
|
5.9529
|
|
5.8059
|
|
5.5886
|
|
5.4309
|
|
5.2775
|
|
5.1611
|
|
5.0845
|
|
5.0365
|
|
5.0081
|
|
4.9920
|
|
4.9832
|
April 15, 2023
|
|
6.1349
|
|
6.1349
|
|
6.1349
|
|
6.1349
|
|
5.5556
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
•
|
if the Stock Price is between two Stock Price amounts on the table or the Effective Date is between two Effective Dates on the table, the Fundamental Change Conversion Rate will be determined by straight-line interpolation between the Fundamental Change Conversion Rates set forth for the higher and lower Stock Price amounts and the earlier and later Effective Dates, as applicable, based on a 365- or 366-day year, as applicable;
|
•
|
if the Stock Price is in excess of $320.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the first row of the table above), then the Fundamental Change Conversion Rate will be the Minimum Conversion Rate; and
|
•
|
if the Stock Price is less than $100.00 per share (subject to adjustment as described above), then the Fundamental Change Conversion Rate will be the Maximum Conversion Rate.
|
Listing:
|
Danaher Corporation intends to apply to have the Series B Mandatory Convertible Preferred Stock listed on The New York Stock Exchange under the symbol “DHR PR B.”
|
CUSIP / ISIN:
|
235851409 / US2358514097
|
Joint Book-Running Managers:
|
Goldman Sachs & Co. LLC
J.P. Morgan Securities LLC |
Co-Managers:
|
Commerz Markets LLC
|
|
|
Very truly yours,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
Name:
|
|
|
|
|
Title:
|
|
DATED:
|
|
|
|
|
1.
|
I am (a) responsible for the financial and accounting matters of the Company and its subsidiaries, including oversight of the financial and accounting functions and staff; (b) knowledgeable about the internal accounting records and accounting practices, systems, policies and procedures of the Company and its subsidiaries; and (c) knowledgeable about establishing and maintaining disclosure controls and procedures and internal control over financial reporting;
|
2.
|
I have (i) read the Registration Statement, and (ii) supervised the compilation of, and reviewed the circled financial information contained in, the Registration Statement attached as Annex A hereto (collectively, the “Financial Information and Data”); and
|
3.
|
To the best of my knowledge after reasonable investigation, the Financial Information and Data is true, correct and accurate in all material respects.
|
By:
|
|
|
Name:
|
|
Title: Chief Financial Officer
|
SECTION 1.
|
Representations and Warranties.
|
SECTION 2.
|
Sale and Delivery to Underwriters; Closing.
|
SECTION 3.
|
Covenants of the Company. The Company covenants with each Underwriter as follows:
|
SECTION 4.
|
Payment of Expenses.
|
SECTION 5.
|
Conditions of Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations and warranties of the Company contained in Section 1 hereof or in certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the provisions hereof, to the performance by the Company of its covenants and other obligations hereunder, and to the following further conditions:
|
SECTION 6.
|
Indemnification.
|
SECTION 7.
|
Contribution. If the indemnification provided for in Section 6 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other hand from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other hand in connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other relevant equitable considerations.
|
SECTION 8.
|
Representations, Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling any Underwriter, its officers or directors or any person controlling the Company, and (ii) delivery of and payment for the Securities.
|
SECTION 9.
|
Termination of Agreement.
|
SECTION 10.
|
Default by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time or a Date of Delivery to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”), the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters, or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such 24-hour period, then:
|
SECTION 11.
|
Tax Disclosure. Notwithstanding any other provision of this Agreement, from the commencement of discussions with respect to the transactions contemplated hereby, the Company (and each employee, representative or other agent of the Company) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure (as such terms are used in Sections 6011, 6111 and 6112 of the U.S. Code and the Treasury Regulations promulgated thereunder) of the transactions contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to the Company relating to such tax treatment and tax structure.
|
SECTION 12.
|
Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Underwriters shall be directed to Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Control Room; J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 622-8358), Attention: Equity Syndicate Desk, Citigroup Global Markets Inc., 388 Greenwich Street, New York, NY 10013, Facsimile: (646) 291-1469, Attention: General Counsel; and Evercore Group L.L.C., 55 East 52nd Street, New York, NY 10055, Attention: Kenneth A. Masotti, Esq., Fax: 212-857-3101, with a copy to Latham & Watkins LLP, 885 3rd Avenue, New York, NY 10022, Attention: Greg Rodgers.
|
SECTION 13.
|
Recognition of the U.S. Special Resolution Regimes.
|
SECTION 14.
|
No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.
|
SECTION 15.
|
Integration. This Agreement supersedes all prior agreements and understandings (whether written or oral) among the Company and the Underwriters, or any of them, with respect to the subject matter hereof.
|
SECTION 16.
|
Parties. This Agreement shall each inure to the benefit of and be binding upon the Underwriters and the Company and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Underwriters and the Company and their respective successors and the controlling persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters and the Company and their respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter shall be deemed to be a successor by reason merely of such purchase.
|
SECTION 17.
|
GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
|
SECTION 18.
|
TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
|
SECTION 19.
|
Waiver of Right to Trial by Jury. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
|
SECTION 20.
|
Submission to Jurisdiction. The Company irrevocably submits to the non-exclusive jurisdiction of any New York State or United States Federal court sitting in The City of New York over any suit, action or proceeding arising out of or relating to this Agreement. The Company irrevocably waives, to the full extent permitted by law, any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding brought in such a court and any claim that any such suit, action or proceeding brought in such a court has been brought in an inconvenient forum. To the extent that the Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the jurisdiction of any court or from any legal process with respect to itself or its property, the Company irrevocably waives, to the full extent permitted by law, such immunity in respect of any such suit, action or proceeding. The Company waives, to the full extent permitted by law, any other requirements of or objections to personal jurisdiction with respect thereto.
|
SECTION 21.
|
Counterparts; Electronic Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all such
|
SECTION 22.
|
Effect of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.
|
Very truly yours,
|
|
|
|
DANAHER CORPORATION
|
|
|
|
By:
|
/s/ Matthew McGrew
|
|
Name: Matthew McGrew
|
|
Title: Executive Vice President and Chief Financial Officer
|
CONFIRMED AND ACCEPTED,
as of the date first above written: |
|
|
|
|
|
|
|
GOLDMAN SACHS & CO. LLC
|
|
|
|
By:
|
/s/ Elizabeth Wood
|
|
Name: Elizabeth Wood
|
|
Title: MD
|
|
|
|
|
J.P. MORGAN SECURITIES LLC
|
|
|
|
By:
|
/s/ David Ke
|
|
Name: David Ke
|
|
Title: Executive Director
|
|
|
|
|
CITIGROUP GLOBAL MARKETS INC.
|
|
|
|
By:
|
/s/ Richard Duffield
|
|
Name: Richard Duffield
|
|
Title: Managing Director
|
|
|
|
|
EVERCORE GROUP L.L.C.
|
|
|
|
By:
|
/s/ James R. Birle, Jr.
|
|
Name: James R. Birle, Jr.
|
|
Title: Senior Managing Director
|
Name of Underwriter
|
|
Number of Initial Securities to be Purchased
|
Goldman Sachs & Co. LLC
|
|
465,000
|
J.P. Morgan Securities LLC
|
|
310,000
|
Citigroup Global Markets Inc.
|
|
232,500
|
Evercore Group L.L.C.
|
|
232,500
|
Credit Suisse Securities (USA) LLC
|
|
116,250
|
Commerz Markets LLC
|
|
19,375
|
Mizuho Securities USA LLC
|
|
19,375
|
MUFG Securities Americas Inc.
|
|
19,375
|
Raymond James & Associates, Inc.
|
|
19,375
|
RBC Capital Markets, LLC
|
|
19,375
|
Scotia Capital (USA) Inc.
|
|
19,375
|
SMBC Nikko Securities, Inc.
|
|
19,375
|
TD Securities (USA) LLC
|
|
19,375
|
U.S. Bancorp Investments, Inc.
|
|
19,375
|
Wells Fargo Securities, LLC.
|
|
19,375
|
|
|
|
Total
|
|
1,550,000
|
1.
|
Pricing Term Sheet, dated May 7, 2020, relating to the Securities, as filed pursuant to Rule 433 under the Securities Act and attached to this Agreement as Schedule D.
|
1.
|
Investor Presentation, dated May 2020.
|
Issuer:
|
Danaher Corporation
|
Trade Date:
|
May 8, 2020
|
Expected Settlement Date:
|
May 12, 2020 (T+2)
|
by Danaher Corporation:
|
9,509,203 shares of common stock, par value $0.01 per share (“Common Stock”), of Danaher Corporation
|
Danaher Corporation:
|
Up to 1,426,379 shares of Common Stock that the underwriters for the Common Stock Offering have the option to purchase from Danaher Corporation.
|
Symbol / Exchange:
|
DHR / NYSE
|
on the NYSE on May 7, 2020:
|
$163.48 per share
|
Public Offering Price:
|
$163.00 per share
|
Net Proceeds:
|
The net proceeds of the Common Stock Offering will be approximately $1.50 billion (or approximately $1.73 billion if the underwriters exercise their option to purchase additional shares of Common Stock in full), after deducting estimated expenses and underwriting discounts and commissions. Danaher Corporation intends to use the net proceeds from the Common Stock Offering and the Series B Mandatory Convertible Preferred Stock Offering for general corporate purposes, which may include, without limitation and in its sole discretion, funding potential future acquisitions and investments, working capital, capital expenditures, investments in or loans to its subsidiaries, refinancing of outstanding indebtedness, refinancing of outstanding capital securities, share repurchases (including, but not limited to, repurchases of its common stock), dividends and satisfaction of other obligations. The precise amounts and timing of these use of proceeds will depend on Danaher Corporation’s funding requirements and those of its subsidiaries.
|
CUSIP / ISIN:
|
235851102 / US2358511028
|
Joint Book-Running Managers:
|
Goldman Sachs & Co. LLC
|
Co-Managers:
|
BTIG, LLC
|
Title of Securities:
|
5.00% Mandatory Convertible Preferred Stock, Series B, without par value, of Danaher Corporation (the “Series B Mandatory Convertible Preferred Stock”)
|
Offered by Danaher Corporation:
|
1,550,000 shares
|
Danaher Corporation:
|
Up to an additional 167,500 shares that the underwriters for the Series B Mandatory Convertible Preferred Stock Offering have the option to purchase, solely to cover over-allotments, if any.
|
Public Offering Price:
|
$1,000.00 per share
|
Insider Participation:
|
One or more entities or individuals affiliated with Steven Rales, the Chairman of our Board, or Mitchell Rales, one of our directors and Chairman of our Executive Committee (collectively, the “Affiliated Entities”), have agreed to purchase 93,300 shares of Series B Mandatory Convertible Preferred Stock (representing an aggregate liquidation preference of up to $93.3 million) in this offering at the public offering price for investment purposes. The underwriters will not receive any underwriting discounts or commissions on any shares of Series B Mandatory Convertible Preferred Stock sold to the Affiliated Entities.
|
Net Proceeds:
|
The net proceeds of the Series B Mandatory Convertible Preferred Stock Offering will be approximately $1.51 billion (or approximately $1.67 billion if the underwriters exercise their over-allotment option in full), after deducting estimated expenses and underwriting discounts and commissions. Danaher Corporation intends to use the net proceeds from the Series B Mandatory Convertible Preferred Stock Offering and the Common Stock Offering for general corporate purposes, which may include, without limitation and in its sole discretion, funding potential future acquisitions and investments, working capital, capital expenditures, investments in or loans to its subsidiaries, refinancing of outstanding indebtedness, refinancing of outstanding capital securities, share repurchases (including, but not limited to, repurchases of its common stock), dividends and satisfaction of other obligations. The precise amounts and timing of these use of proceeds will depend on Danaher Corporation’s funding requirements and those of its subsidiaries.
|
Liquidation Preference:
|
$1,000.00 per share
|
Dividends:
|
5.00% of the liquidation preference of $1,000 per share of the Series B Mandatory Convertible Preferred Stock per annum. Dividends shall accumulate from the most recent date as to which dividends shall have been paid or, if no dividends have been paid, from the first original issue date, whether or not in any dividend period or periods there have been funds legally available for the payment of such dividends, and, to the extent that
|
Floor Price:
|
$57.05, subject to adjustment as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Dividend Payment Dates:
|
January 15, April 15, July 15 and October 15 of each year, commencing on July 15, 2020, to, and including, April 15, 2023.
|
Dividend Record Dates:
|
The December 31, March 31, June 30 or September 30, as applicable, immediately preceding the applicable Dividend Payment Date.
|
Dividend Threshold:
|
$0.18 per share, subject to adjustment as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Initial Price:
|
$163.00, which equals the per share public offering price of the Common Stock in the Common Stock Offering.
|
Threshold Appreciation Price:
|
$199.68, which represents an appreciation of 22.5% over the Initial Price.
|
Mandatory Conversion Date:
|
The second business day immediately following the last Trading Day of the 20 consecutive Trading Day period beginning on, and including, the 21st scheduled Trading Day immediately preceding April 15, 2023. The Mandatory Conversion Date is expected to be April 15, 2023.
|
Conversion Rate:
|
Upon conversion on the mandatory conversion date, the conversion rate for each share of the Series B Mandatory Convertible Preferred Stock will be not more than 6.1349 shares of Common Stock (the “Maximum Conversion Rate”) and not less than 5.0081 shares of Common Stock (the “Minimum Conversion Rate”), with the exact conversion rate depending on the Applicable Market Value of the Common Stock, as described in, and subject to certain anti-dilution adjustments that are described in, the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement. The following table illustrates hypothetical conversion rates per share of the Series B Mandatory Convertible Preferred Stock, subject to certain anti-dilution adjustments that are described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Applicable Market Value
of the Common Stock
|
|
Conversion rate (number of shares
of Common Stock to be received
upon conversion of each share of the
Series B Mandatory Convertible Preferred Stock)
|
|
|
|
Greater than $199.68 (which is
the Threshold Appreciation Price)
|
|
5.0081 shares (approximately equal to $1,000 divided
by the Threshold Appreciation Price) (the initial
Minimum Conversion Rate)
|
|
|
|
Equal to or less than $199.68 but
greater than or equal to $163.00
|
|
Between 5.0081 and 6.1349 shares, determined by
dividing $1,000 by the Applicable Market Value
of the Common Stock
|
|
|
|
Less than $163.00 (which is the
Initial Price)
|
|
6.1349 shares (approximately equal to
$1,000 divided by the Initial Price) (the initial
Maximum Conversion Rate)
|
of the Holder:
|
At any time prior to April 15, 2023, other than during a Fundamental Change Conversion Period (as defined below), holders of the Series B Mandatory Convertible Preferred Stock have the option to elect to convert their shares of the Series B Mandatory Convertible Preferred Stock in whole or in part (but in no event less than one share of the Series B Mandatory Convertible Preferred Stock), into shares of Common Stock at the Minimum Conversion Rate of 5.0081 shares of Common Stock per share of Series B Mandatory Convertible Preferred Stock as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement. This Minimum Conversion Rate is subject to certain anti-dilution adjustments as described in the Series B Mandatory Convertible Preferred Stock Preliminary Prospectus Supplement.
|
Dividend Make-Whole Amount:
|
If a Fundamental Change occurs on or prior to April 15, 2023, holders of the Series B Mandatory Convertible Preferred Stock will have the option to convert their shares of Series B Mandatory Convertible Preferred Stock, in whole or in part (but in no event less than one share of the Series B Mandatory Convertible Preferred Stock), into Common Stock at the Fundamental Change Conversion Rate during the period (“Fundamental Change Conversion Period”) beginning on the effective date of such Fundamental Change and ending on, and including, the date that is 20 calendar days after the Effective Date of such Fundamental Change (or, if earlier, April 15, 2023). The Fundamental Change Conversion Rate will be determined based on the Effective Date of the Fundamental Change and the price paid or deemed paid per share of the Common Stock in such Fundamental Change.
|
Conversion Rate:
|
The “Fundamental Change Conversion Rate” will be determined by reference to the table below and is based on the Effective Date and the Stock Price. If the holders of Common Stock receive only cash in the Fundamental Change, the Stock Price shall be the cash amount paid per share of Common Stock. Otherwise, the Stock Price shall be the Average VWAP per share of Common Stock over the 10 consecutive Trading Day period ending on, and including, the Trading Day preceding the Effective Date.
|
|
|
Stock Price
|
||||||||||||||||||||||
Effective Date
|
|
$100.00
|
|
$120.00
|
|
$140.00
|
|
$163.00
|
|
$180.00
|
|
$199.68
|
|
$220.00
|
|
$240.00
|
|
$260.00
|
|
$280.00
|
|
$300.00
|
|
$320.00
|
May 12, 2020
|
|
5.7253
|
|
5.6137
|
|
5.4906
|
|
5.3571
|
|
5.2713
|
|
5.1880
|
|
5.1196
|
|
5.0673
|
|
5.0275
|
|
4.9976
|
|
4.9753
|
|
4.9588
|
April 15, 2021
|
|
5.8696
|
|
5.7579
|
|
5.6171
|
|
5.4527
|
|
5.3438
|
|
5.2383
|
|
5.1531
|
|
5.0905
|
|
5.0449
|
|
5.0126
|
|
4.9900
|
|
4.9745
|
April 15, 2022
|
|
6.0298
|
|
5.9529
|
|
5.8059
|
|
5.5886
|
|
5.4309
|
|
5.2775
|
|
5.1611
|
|
5.0845
|
|
5.0365
|
|
5.0081
|
|
4.9920
|
|
4.9832
|
April 15, 2023
|
|
6.1349
|
|
6.1349
|
|
6.1349
|
|
6.1349
|
|
5.5556
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
•
|
if the Stock Price is between two Stock Price amounts on the table or the Effective Date is between two Effective Dates on the table, the Fundamental Change Conversion Rate will be determined by straight-line interpolation between the Fundamental Change Conversion Rates set forth for the higher and lower Stock Price amounts and the earlier and later Effective Dates, as applicable, based on a 365- or 366-day year, as applicable;
|
•
|
if the Stock Price is in excess of $320.00 per share (subject to adjustment in the same manner as the Stock Prices set forth in the first row of the table above), then the Fundamental Change Conversion Rate will be the Minimum Conversion Rate; and
|
•
|
if the Stock Price is less than $100.00 per share (subject to adjustment as described above), then the Fundamental Change Conversion Rate will be the Maximum Conversion Rate.
|
Listing:
|
Danaher Corporation intends to apply to have the Series B Mandatory Convertible Preferred Stock listed on The New York Stock Exchange under the symbol “DHR PR B.”
|
CUSIP / ISIN:
|
235851409 / US2358514097
|
Joint Book-Running Managers:
|
Goldman Sachs & Co. LLC
J.P. Morgan Securities LLC |
Co-Managers:
|
Commerz Markets LLC
|
|
|
Very truly yours,
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
Name:
|
|
|
|
|
Title:
|
|
DATED:
|
|
|
|
|
1.
|
I am (a) responsible for the financial and accounting matters of the Company and its subsidiaries, including oversight of the financial and accounting functions and staff; (b) knowledgeable about the internal accounting records and accounting practices, systems, policies and procedures of the Company and its subsidiaries; and (c) knowledgeable about establishing and maintaining disclosure controls and procedures and internal control over financial reporting;
|
2.
|
I have (i) read the Registration Statement, and (ii) supervised the compilation of, and reviewed the circled financial information contained in, the Registration Statement attached as Annex A hereto (collectively, the “Financial Information and Data”); and
|
3.
|
To the best of my knowledge after reasonable investigation, the Financial Information and Data is true, correct and accurate in all material respects.
|
By:
|
|
|
Name:
|
|
Title: Chief Financial Officer
|
/s/ James F. O’Reilly
|
Name: James F. O’Reilly
|
Title: Vice President, Associate General
Counsel and Secretary
|
|
|
Stock Price
|
||||||||||||||||||||||
Effective Date
|
|
$100.00
|
|
$120.00
|
|
$140.00
|
|
$163.00
|
|
$180.00
|
|
$199.68
|
|
$220.00
|
|
$240.00
|
|
$260.00
|
|
$280.00
|
|
$300.00
|
|
$320.00
|
May 12, 2020
|
|
5.7253
|
|
5.6137
|
|
5.4906
|
|
5.3571
|
|
5.2713
|
|
5.1880
|
|
5.1196
|
|
5.0673
|
|
5.0275
|
|
4.9976
|
|
4.9753
|
|
4.9588
|
April 15, 2021
|
|
5.8696
|
|
5.7579
|
|
5.6171
|
|
5.4527
|
|
5.3438
|
|
5.2383
|
|
5.1531
|
|
5.0905
|
|
5.0449
|
|
5.0126
|
|
4.9900
|
|
4.9745
|
April 15, 2022
|
|
6.0298
|
|
5.9529
|
|
5.8059
|
|
5.5886
|
|
5.4309
|
|
5.2775
|
|
5.1611
|
|
5.0845
|
|
5.0365
|
|
5.0081
|
|
4.9920
|
|
4.9832
|
April 15, 2023
|
|
6.1349
|
|
6.1349
|
|
6.1349
|
|
6.1349
|
|
5.5556
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|
|
5.0081
|